Cryolipolysis adverse events: what 11,280 FDA MAUDE reports reveal

Cryolipolysis — marketed by its inventor as CoolSculpting — is the most widely performed nonsurgical fat-reduction procedure in the United States, with the manufacturer reporting more than seven million treatments worldwide since the device was first cleared in 2010. The pitch is simple: a vacuum applicator pulls a fold of skin and fat between cooling plates, holds the tissue below freezing long enough to crystallize the lipid-rich adipocytes, and the body clears the dead cells over the following weeks. For most patients it works, and the recovery is a few hours of redness and numbness.

But the FDA's postmarket device database tells a different and much narrower story about what goes wrong. An analysis of 11,280 adverse-event reports filed under FDA product code OOK ("Dermal Cooling Pack/Vacuum/Massager," 21 CFR 878.4340) — the code that covers vacuum-and-cooling cryolipolysis systems — received between 2011 and May 2026 found that a single complication dominates the safety record almost completely: paradoxical adipose hyperplasia, the condition in which treated fat grows back larger and firmer instead of shrinking.

That finding is not what the device's marketing, its patient materials, or even most clinical reviews emphasize. It is what the reports themselves say.

For the broader picture of how cryolipolysis compares with aesthetic lasers and other energy devices in the FDA's injury data, see energy-device injuries in the MAUDE data. This article is the dedicated cryolipolysis drill-down: the PAH dominance that drives the headline number, and — what the headline crowds out — the non-PAH injury spectrum, the hernia signal, and the patient epidemiology that an informed-consent conversation usually omits.

The dataset at a glance

MAUDE (Manufacturer and User Facility Device Experience) is the FDA's passive-surveillance system for medical devices. It aggregates mandatory manufacturer reports, mandatory user-facility reports, and voluntary reports from patients and clinicians. It is well known to underreport — the cases that surface are a fraction of real-world events, and a report records an event that followed a treatment, not proof that the device caused it. Used carefully, MAUDE shows what kinds of events actually surface, in what proportion, and when. It cannot be used to calculate how often PAH happens in the real world.

Every record in this dataset represents one patient (all 11,280 reports carry a single-patient flag; none is a batched summary). That matters: these are not 11,280 patients rolled up into a handful of manufacturer mega-reports.

PAH is not the rare footnote the brochure implies

The headline number is that 10,730 of 11,280 cryolipolysis reports — 95.1% — describe paradoxical adipose hyperplasia. Read literally, that means almost every adverse event serious enough to reach the FDA's device database after a CoolSculpting treatment is the same complication: a firm, rubbery, visibly enlarged mass of tissue that appears in the exact shape of the applicator, two to six months after the session, and does not go away on its own.

That proportion needs context, because PAH is described almost everywhere as "rare." It is uncommon as a fraction of all cryolipolysis treatments — the independent pooled-incidence estimate sits well under one percent, and even higher real-world single-center figures remain below half a percent. But PAH is overwhelming as a fraction of all reported problems: if something goes wrong badly enough to be reported after cryolipolysis, it is almost always PAH. (For the incidence numbers, the 2025 meta-analysis behind them, and which patients are at elevated risk, see CoolSculpting PAH risk; the point this dataset adds is different — what lives in the other five percent.)

A few representative narratives, lightly edited to remove redacted fields, show the consistent pattern:

"A month post treatment the patient reported experiencing pain, numbness, firmness and visible enlargement. On [date] the patient was assessed by a physician who diagnosed the areas with paradoxical [adipose hyperplasia]."

"I had eight CoolSculpting cycles on my body; four on my abdomen and two on each flank… I started to notice a well-demarcated mass in my abdomen where I had received the CoolSculpting treatments and fluffy fat which resulted in an enlargement of my flanks."

"You can actually see the outline of where the cool sculpting paddles were placed."

What patients describe is a hard, defined bulge — often asymmetric — that mirrors the applicator footprint, develops gradually, and resists diet and exercise because it is a structural enlargement of the fat pad rather than a storage of excess calories. Almost 96% of PAH reports in this dataset mention a firm, hard, enlarged mass or visible distortion, and a similar share reference a corrective procedure such as liposuction, lipectomy, or excision. The standard treatment is surgical, because the enlarged tissue does not respond to further non-invasive contouring.

A reporting surge that began in 2021

The PAH reports are not spread evenly across the device's fifteen-year history. They cluster violently in a three-year window.

Through 2020, PAH appeared in MAUDE only a handful of times per year. In 2021 the count jumped to over a thousand, and it peaked at 5,441 reports in 2023 — more than a thousand times the 2019 level — before declining. Several forces almost certainly converged: rising treatment volume as the installed base of CoolSculpting and the newer CoolSculpting Elite systems expanded through the late 2010s; growing patient awareness that the firm bulge they were seeing had a name and was a recognized device complication; litigation and media coverage that gave patients a reason to file; and a manufacturer that, as the narratives show, was actively submitting individual MDRs for each PAH complaint it received. The decline after 2023 likely reflects the natural clearing of a reporting backlog rather than a fall in real-world incidence — MAUDE counts reports received, and a burst of retrospective filings eventually exhausts itself.

The practical point for a patient reading this today is that the low pre-2021 counts do not mean PAH was rare before 2021. They mean it was underreported before the reporting environment changed.

Who is reporting, and on what equipment

Cryolipolysis MAUDE is overwhelmingly a manufacturer-reported, Allergan-dominated dataset. 11,129 reports (98.7%) were submitted by the manufacturer rather than filed voluntarily by patients or clinicians, and 11,034 (97.9%) name Allergan or ZELTIQ equipment — the CoolSculpting System and its successor, the CoolSculpting Elite System, both manufactured at Allergan's Pleasanton, California facility (Allergan acquired ZELTIQ Aesthetics, the original developer, in 2017). This concentration reflects market share rather than a device defect unique to one brand: CoolSculpting is the dominant installed cryolipolysis platform in the U.S., so it generates the bulk of the exposure and therefore the bulk of the reports.

Among the reports that name a specific applicator, the CoolAdvantage family (CoolAdvantage, CoolAdvantage Plus, CoolCore, and CoolCurve / CoolCurve+) dominates, followed by CoolMax, CoolFit, CoolMini (the small submental applicator), and CoolSmooth. The treatment sites named most often in the narratives are the abdomen and the flanks — the two areas CoolSculpting was first cleared for — followed by the submental area, the back, the thighs, and the upper arms. This mirrors the body areas where cryolipolysis is most commonly performed rather than pointing to any single site as uniquely risky.

On patient sex, women outnumber men roughly three to one among reports where sex is recorded (7,015 female vs. 2,258 male), which tracks the overall cosmetic-procedure population. What is notable is that men make up about 24% of sexed PAH reports — a higher share than men hold of most cosmetic procedures — consistent with the clinical literature repeatedly identifying male sex as a PAH risk factor along with abdominal treatment and repeated cycles.

The other five percent: frostbite, burns, nerve, and scarring

PAH crowds out everything else in the dataset, but the remaining 571 reports describe the spectrum of non-PAH injuries a cooling-and-vacuum device can produce. Within that group the most frequent themes are:

• Firmness, nodules, or a mass without a clear PAH label (about 31%) — likely early or mild PAH that was not coded as such, or localized induration.
• Pain and tenderness (about 19%), including late-onset pain that appears weeks after treatment — a recognized cryolipolysis phenomenon.
• Burns and thermal injury (about 13%) and cold injury — frostbite, freezing injury, ice burn (about 11%). Cryolipolysis deliberately freezes tissue, and the line between therapeutic freezing and a cold injury is a function of applicator fit, skin temperature, and cycle parameters.
• Numbness and nerve symptoms (about 13%) and scarring (about 12%), the latter usually a consequence of a deeper thermal or cold injury that healed with fibrosis.
• Skin discoloration and pigment change (about 8%), including hyperpigmentation after an inflamed or blistered area healed.

These are the same complications the clinical literature describes as occasional cryolipolysis effects — they are real, but they are dwarfed, in the reporting data, by PAH. One further signal sits outside the PAH bucket but is worth naming: 120 reports mention a hernia, most of them inguinal or periumbilical hernias diagnosed in the months after abdominal CoolSculpting and attributed to the treatment in the narrative. A 2022 peer-reviewed analysis of cryolipolysis device reports in Lasers in Surgery and Medicine flagged 47 such hernia cases through 2021; this dataset, running through May 2026, captures roughly two and a half times that count. The mechanism is not established and the reports are few relative to treatment volume, but a hernia is a surgical problem, and it is the kind of unexpected, non-cosmetic outcome that belongs in a candid informed-consent discussion.

Two records in this dataset are coded with an event type of "Death," but neither narrative describes a patient fatality: one is a complaint about consumable cartridge costs, and the other is a social-media report the manufacturer could not corroborate. Broader tallies that include related cooling-system product codes surface a few additional death-coded reports, but none establishes that cryolipolysis caused a fatality. The count of death-coded reports shifts with how wide the product-code filter is set; the substantive point does not — no confirmed cryolipolysis-attributed death is documented in the MAUDE record.

What this means if you are considering cryolipolysis

None of this is an argument against cryolipolysis as a technology. For the right candidate — close to goal weight, with discrete, pinchable fat bulges, and realistic expectations about a modest (roughly 20–25%) reduction in the treated fat layer — it remains a reasonable option. The data is an argument for informed consent that reflects what the device's own safety record actually says.

The questions worth asking before treatment are concrete:

• "What is paradoxical adipose hyperplasia, and what is your clinic's actual experience with it?" A provider who cannot describe PAH, or who quotes only the manufacturer's one-in-4,000 figure without acknowledging the independent 0.22% pooled estimate, has not engaged with the literature. PAH is the dominant complication of this device; the conversation should reflect that.
• "What happens if I develop a firm bulge two to five months after treatment?" PAH does not resolve on its own and does not respond to further cryolipolysis; the standard correction is liposuction or direct excision. Ask whether the clinic counsels patients on this before treatment, and how corrective costs are handled. Many of the MAUDE narratives describe patients who were told the enlargement would subside and did not.
• "Which applicator are you using, and why?" Different applicators suit different areas and body types; an applicator that does not fit the contour cleanly increases the risk of uneven energy delivery.
• "Am I a higher-risk patient?" Male sex, abdominal treatment, and repeat cycles are repeatedly associated with PAH in the literature. These are not contraindications, but they are reasons to weigh the decision more carefully.

Cryolipolysis is elective, non-urgent, and performed on otherwise healthy people almost entirely for cosmetic benefit. That puts the burden on the patient and the provider to make sure the decision is an informed one — and the FDA's own device database is the clearest available record of what informed consent for this device needs to cover.

Sources

• U.S. FDA, MAUDE (Manufacturer and User Facility Device Experience) public database — analysis of 11,280 adverse-event reports under product code OOK ("Dermal Cooling Pack/Vacuum/Massager," 21 CFR 878.4340), received 2011 – May 2026 (run June 2026): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm
• U.S. FDA, 510(k) Premarket Notification K151179 — ZELTIQ CoolSculpting System, clearance for cold-assisted lipolysis of the submental area (BMI ≤ 30): https://www.accessdata.fda.gov/cdrh_docs/pdf15/k151179.pdf
• U.S. FDA, Device Classification Regulation 21 CFR 878.4340 — Contact Cooling System for Aesthetic Use (Class II): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=878.4340
• Incidence of Paradoxical Adipose Hyperplasia After Cryolipolysis: A Systematic Review and Meta-Analysis (pooled incidence 0.22%, 95% CI 0.10–0.47) — PMC (NCBI): https://pmc.ncbi.nlm.nih.gov/articles/PMC12662051
• Adverse-event analysis of noninvasive body-contouring device reports in MAUDE, 2015–2021 (723 medical device reports; PAH 73.2%; hernia cases attributed to CoolSculpting) — Lasers in Surgery and Medicine, reported via MDedge Dermatology: https://www.mdedge.com/dermatology/article/258284-aesthetic-dermatology/body-contouring-tops-list-cosmetic-procedures
• A Systematic Review of Paradoxical Adipose Hyperplasia (PAH) Post-Cryolipolysis — Journal of Drugs in Dermatology: https://jddonline.com/articles/a-systematic-review-of-paradoxical-adipose-hyperplasia-pah-post-cryolipolysis-S1545961617P0062X
• ASPS (American Society of Plastic Surgeons), National Plastic Surgery Statistics (nonsurgical fat-reduction procedure volume): https://www.plasticsurgery.org/documents/News/Statistics/2023/plastic-surgery-statistics-full-report-2023.pdf